Prostat Kanseri Tedavisinde Fokal Tedaviler

Minimal invaziv yöntemleri kullanarak normal prostat dokusunu, nörovaskuler demeti ve sfinkteri koruyarak prostata sınırlı kanserin ablasyonu Fokal Terapi ( FT) olarak tanımlanır. Günümüzde FT seçenekleri high-intensity focused ultrasound (HIFU), kriyoteapi, focal laser ablasyon (FLA), irreversible electroporation (IRE), vascular targeted photodynamic therapy (VTP), focal brakiterapi (FBT) gibi yöntemler kullanılarak yapılabilir. Yeni modaliteler de sürekli tanımlanmakta olup hangi modalitenin daha avantajlı olduğu konusunda kesin bir öneri henüz oluşmamıştır. Bu derlemede FT de kulanılan metodların sonuçları literatür eşliğinde gözden geçirilmiştir

Anahtar Kelimeler:

focal, prostat, kanser

Focal Treatments for Prostate Cancer

Focal therapy ( FT ) in treatment of prostate cancer has been defined as ablation of index lesion by preserving of normaltissue, neurovascular bundle and urinary sphincter. With growing interest in focal herapy (FT) of prostate cancer(PCa) there is an increasing armamentarium of treatment modalities including high-intensity focused ultrasound(HIFU), cryotherapy, focallaser ablation (FLA), irreversible electroporation (IRE), vascular targeted photodynamictherapy (VTP), focal brachytherapy (FBT ). Untill now, there is no concencus on which treatment modality has moreadvantageous. We reviewed current FT alternatives on the treatment of prostate cancer.

Keywords:

Prostate cancer, focal treatment, ablation,

PDF

___

1- Jemal A, Siegel R, Ward E ve ark. Cancer statistics. CA Cancer J Clin 57: 43-66,2007
2- Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J UrolNephrol 14: 29-35,1980;
3-Yatani R, Chigusa I, Akazaki K ve ark.Geographic pathology of latent prostaticcarcinoma. Int J Cancer 29: 611-6, 1982
4- Kikuchi E, Scardino PT, Wheeler TM,Slawin KM, Ohori M. Is tumor volüme an independent prognostic factor in clinically localized prostate cancer? J Urol 172:508–11, 2004
5- Hernandez DJ, Nielsen ME, Han M, et al.Natural history of pathologically organconfined (pT2),Gleason score 6 or less,prostate cancer after radical prostatectomy. Urology 72:172–6,2008
6- Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 =4 + 3? J Clin Oncol 27:3459–64,2009
7-Murphy DG, Loeb S. Prostate cancer: growth of AS in the USA signals reduction in overtreatment. Nat Rev Urol 12:604–5,2015
8-Tsivian M, Abern MR, Polascik TJ. Evolution of the concept of focal therapy for prostate cancer. Oncology 27:64–68,2013
9- van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A,Cussenot O, et al. Role of active surveillance and focal therapy inlow- and intermediate-risk prostate cancers. World J Urol 33:907–16, 2015
10- Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol 26:457–67,2008
11-Bahn D, Silverman P, Lee F, Badalament R, Bahn ED, Rewcastle JC. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 20:688–92, 2006
12- Blana A, Murat FJ, Walter B, et al. First analysis of long-term results with transrectal HIFU inpatients with localized prostate cancer. Eur Urol 53:1194–1203,2008
13- Uchida T, Ohkusa H, Nagata Y, et al.Treatment of localized prostate cancer usinghigh-intensity focused ultrasound. BJU Int 97:56-61 ,2006
14- Ahmed S, Lindsey B, Davies J. Emerging minimally invasive techniques for treating localized prostate cancer. BJU Int. 96(9): 1230-4,2005
15- Salgaonkar VA, Prakash P, Rieke V, Ozhinsky E, Plata J, Kurhanewicz J, et al. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys. 41: 301, 2014
16- Ganzer R,Hadaschik B,Pahernik S,Koch D,Baumunk D,Kuru T,et al. Prospective multicenter phase II-study on focal therapy (hemiablation) of the prostate with High Intensity focused ultrasound (HIFU). J Urol 199:983–989,2017
17- Rischmann P, Gelet A, Riche B, Villers A, Pasticier G, Bondil P,et al. Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol. 71:267–73,2016
18- Feijoo ER, Sivaraman A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Prapotnich D, Cathala N, Mombet A, Cathelineau X. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol. 69(2):214-20 ,2016
19-Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N,Hindley RG, et al. Focal ablation targeted to the index lesion inmultifocal localised prostate cancer: a prospective development study. Eur Uro 927–36,2015
20- van Velthoven R, Aoun F, Marcelis Q, Albisinni S, Zanaty M, Lemort M, Peltier A, Limani K.A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 19(1):79-83, 2016
21- Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM,Validire P, et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 63:618–22,2013
22- Ellis DS, Manny TBJ, Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 70:9–15, 2007
23- Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) registry. BJU Int 109:1648–54,2012
24- Natarajan S, Jones TA, Priester AM, Geoghegan R, Lieu P, Delfin M, et al. Focal laser ablation of prostate cancer: feasibility of magnetic resonance imaging-ultrasound fusion for guidance. J Urol 198:839–47, 2017
25- Eggener SE, Yousuf A, Watson S, Wang S, Oto A. Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol 196:1670–5, 2016
26- Lepor H, Llukani E, Sperling D, Futterer JJ. Complications,recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. Eur Urol 68:924–6,2015
27- Cepek J, Chronik BA, Lindner U, Trachtenberg J, Davidson SR, Bax J, Fenster A A system for MRI-guided transperineal delivery of needles to the prostate for focal therapy.Med Phys 40(1), 2013
28- Azzouzi A-R, Vincendeau S, Barret E, Cicco A, Kleinclauss F,van der Poel HG, et al. Padeliporfin vascular-targeted photo-dynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label,phase 3, randomised controlled trial. Lancet Oncol 18:181–91, 2016
29- Moore CM, Azzouzi AR, Barret E, Villers A, Muir GH, Barber NJ, Bott S, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy..BJU Int. 116(6):888-96,2015
30- Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, PCM301 Study Group Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.Lancet Oncol 18(2):181-191,2017
31- Cosset JM, Cathelineau X, Wakil G, Pierrat N, Quenzer O, Prapotnich D, et al. Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy 12:331–7, 2013
32-Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM,Validire P, et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 63:618–22, 2013
33- Onik G, Rubinsky B. Irreversible electroporation. Berlin, Heidelberg: Springer-Verlag; 2010. p. 235–47
34- van den Bos W, Muller BG, de la Rosette JJ. A randomized controlled trial on focal therapy for localized prostate carcinoma: hemiablation versus complete ablation with irreversible electroporation. J Endourol 27:262–4,2013
35-Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L,Shnier R, et al. Initial assessment of safety and clinical feasibilityof irreversible electroporation in the focal treatment of prostatecancer. Prostate Cancer Prostatic Dis 17:343–7,2014
36- Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH.Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis. 2017
37- Valerio M, Cerantola Y, Eggener S, Lepor H, Polascik TJ, Villers A, Emberton M. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol 71(1):17-34,2017